Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06533527 · ClinicalTrials.gov registry record · Phase 4

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

A Phase 4 study of Obesity and Diabetes Mellitus, Type 2, sponsored by The Cleveland Clinic.

Completed
Registry status
Phase 4
Development phase
69
Enrollment target
2
Study locations

NCT06533527 is a Phase 4 study of Obesity and Diabetes Mellitus, Type 2 that has completed, run by The Cleveland Clinic. The registered enrollment target is 69 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06533527, a Phase 4 study of Obesity and Diabetes Mellitus, Type 2, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
Phase 4
Development phase
69 participants
Enrollment target
2
Study locations

Study Summary

To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV). Primary Outcomes: * Residual gastric volume that precludes adequate endoscopic examination * Residual gastric volume that necessitates premature termination of the endoscopy procedure * Need for endotracheal intubation due to stomach contents. * Occurrence of aspiration events requiring extended observation/monitoring, unplanned therapeutics, and/or hospital admission Secondary Outcomes: * Presence of any solid food * Presence of moderate liquid content * Increased RGV(Residual Gastric Volume) defined as any amount of solid content or \> 0.8 mL/Kg of fluid content (measured from the aspiration/suction canister). * Differences in primary and secondary outcomes between different medications

Conditions Studied

Obesity Diabetes Mellitus, Type 2 Gastroparesis

Interventions

  • DRUG GLP-1 medication

Study Locations (2)

Florida

  • Cleveland Clinic - Weston

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2024-07-31
Est. Completion 2025-05-20
Phase Phase 4

Sponsor

The Cleveland Clinic

688 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06533527

The ClinicalTrials.gov registry entry for NCT06533527 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which GLP-1 medication is the first listed.

NCT06533527 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Ohio.

Frequently Asked Questions

What is clinical trial NCT06533527 about?

NCT06533527 is a clinical study titled "Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy". To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV). Primary Outcomes: * Residual gastric volume that precludes adequate endoscopic examination * Residual gastric volume that necessitates premature terminatio...

What is the current status of trial NCT06533527?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 69 participants. The study started on 2024-07-31. Estimated completion is 2025-05-20.

What conditions does trial NCT06533527 study?

This clinical trial studies the following conditions: Obesity, Diabetes Mellitus, Type 2, Gastroparesis.

What interventions are being tested in trial NCT06533527?

The interventions under investigation include: GLP-1 medication (DRUG).

Who is sponsoring clinical trial NCT06533527?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06533527 being conducted?

This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Diabetes Mellitus, Type 2

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.